Inicio › Leucemia linfocítica crónica › Indiana
Ensayos clínicos de Leucemia linfocítica crónica en Indiana
12 estudios sobre Leucemia linfocítica crónica buscan participantes en Indiana.
Ciudades en Indiana
Texto oficial del estudio (inglés)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- UChicago Medicine Northwest Indiana, Crown Point
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT04269902A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06697184A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Fort Wayne Medical Oncology and Hematology ( Site 5444), Fort Wayne
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fort Wayne Oncology and Hematology, Fort Wayne
- Hematology Oncology of Indiana, Indianapolis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221500Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- Hematology Oncology of Indiana, Indianapolis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT07516093A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 may 2026 · NCT07582432A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Northwest Cancer Center - Dyer Clinic /ID# 268478, Dyer
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- American Oncology Partners, Fort Wayne
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT05602363Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Goshen Center for Cancer Care, Goshen
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2022 · NCT04502394De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.